Bendamustine in the treatment of chronic lymphocytic leukemia

Expert Review of Anticancer Therapy

Volumn 9, Issue 2, 2009, Pages 165-174

  Knauf, Wolfgang ^a  

^a Onkologische Gemeinschaftspraxis   (Germany)

Author keywords

Alkylating agent; Antimetabolite; Bendamustine; Chemotherapy; Chronic lymphocytic leukemia

Indexed keywords

BENDAMUSTINE; CHLORAMBUCIL; DNA; FLUDARABINE; MELPHALAN; MITOXANTRONE; PREDNISONE; RITUXIMAB; ANTINEOPLASTIC AGENT; CHLORMETHINE DERIVATIVE;

ALOPECIA; ANEMIA; APOPTOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DISTRIBUTION VOLUME; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EXCISION REPAIR; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; LEUKOPENIA; MAXIMUM TOLERATED DOSE; MITOSIS; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SOLID TUMOR; STRUCTURE ANALYSIS; SURVIVAL RATE; THROMBOCYTOPENIA; ADULT; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; REVIEW; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOPENIA; NITROGEN MUSTARD COMPOUNDS; TREATMENT OUTCOME;

EID: 64349123114     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.2.165     Document Type: Article

References (43)

1. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N. Engl. J. Med. 333, 1052-1057 (1995).
2. Kalil N, Cheson BD. Chronic lymphocytic leukemia. Oncologist 4, 352-369 (1999).
3. Jemal A, Siegel R, Ward E et al. Cancer statistics 2008. CA Cancer J. Clin. 58, 71-96 (2008).
4. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukaemia. Blood 46, 219-234 (1975).
5. Binet JL, Auguier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukaemia derived from a multivariate survival analysis. Cancer 48, 198-216 (1981).
6. Hallek M, Cheson B, Catovsky D et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 111, 5446-5456 (2008).
7. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): a randomised controlled trial. Lancet 370, 230-239 (2007).
8. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343, 1750-1757 (2000).
9. Steurer M, Pall G, Richards S et al. Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. Cancer Treat. Rev. 32, 377-389 (2006).
10. Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 23, 4079-4088 (2005).
11. Tam CS, O'Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide and rituximab regimen as initial therapy of chronic lymphocytic leukaemia. Blood 112, 975-980 (2008).
12. Herold M, Keinert K, Anger G et al. Risk-adapted combined radiotherapy and chemotherapy for Hodgkin's disease - a 10-year follow-up. Onkologie 22, 310-313 (1999).
13. Herold M, Schulze A, Niederwieser D et al. Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle lymphoma: results of a randomized Phase III trial (OSHO #19). J. Cancer Res. Clin. Oncol. 132, 105-112 (2006).
14. Pönisch W, Mitrou PS, Merkle K et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone - a randomized Phase III study of the East German Study Group of Hematology and Oncology (OSHO). J. Cancer Res. Clin. Oncol. 132, 205-212 (2006).
15. Leoni LM, Bailey B, Reifert J et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin. Cancer Res. 14, 309-317 (2008).
16. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7, 415-421 (1996).
17. Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18, 1272-1282 (2004).
18. Schwänen C, Hecker T, Hübiner G et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 16, 2096-2105 (2002).
19. Chow KU, Sommerlad WD, Boehrer S et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 87, 33-43 (2002).
20. Rummel MJ, Chow KU, Hoelzer D, Mitrou PS, Weidmann E. In vitro studies with bendamustine: enhanced activity in combination with rituximab. Semin. Oncol. 29(Suppl. 13), 12-14 (2002).
21. Rasschaert M, Schrijvers D, Van den Brande J et al. A Phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours. Br. J. Cancer 96, 1692-1698 (2007).
22. Rasschaert M, Schrijvers D, Van den Brande J et al. A Phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors. Anticancer Drugs 18, 587-595 (2007).
23. Chovan JP, Li F, Yu E, Ring SC. Metabolic profile of [(14)C]bendamustine in rat urine and bile: preliminary structural identification of metabolites. Drug Metab. Dispos. 35, 1744-1753 (2007).
24. Kath R, Blumenstengel K, Fricke HJ, Höffken K. Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol. 127, 48-54 (2001).
25. Aivado M, Schulte K, Henze L, Burger J, Finke J, Hass R. Bendamustine in the treatment of chronic lymphocytic leukemia: results and future perspectives. Semin. Oncol. 4(Suppl. 13), 19-22 (2002).
26. Bergmann MA, Goebeler ME, Herold M et al. Efficacy of bendamustine in patients with relapsed or refractory chromic lymphocytic leukemia: results of a Phase I/II study of the German CLL Study Group. Haematologica 90, 1357-1364 (2005).
27. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pretreated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J. Cancer Res. Clin. Oncol. 132, 99-104 (2005).
28. Köppler H, Heymanns J, Pandorf A, Weide R. Bendamustine plus mitoxantrone - a new effective treatment for advanced chronic lymphocytic leukaemia: results of a Phase I/II study. Leuk. Lymphoma 45, 911-913 (2004).
29. Bremer K. High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin's-lymphomas. J. Cancer Res. Clin. Oncol. 128, 603-609 (2002).
30. Weide R, Pandorf A, Heymanns J, Köppler H. Bendamustine/ mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk. Lymphoma 45, 2445-2449 (2004).
31. Niederle N, Balleisen L, Heit W et al. Bendamustine vs. fludarabine as second-line treatment for patients with chronic lymphocytic leukemia - first interim results of a randomized study. Ann. Oncol. 19(Suppl. 4), iv194 (2008) (Abstract 379).
32. Fischer K, Stilgenbauer S, Schweighofer CD et al. Bendamustine in combination with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre Phase II trial of the German CLL Study Group (GCLLSG). Blood 112, (2008) (Abstract 330).
33. Knauf WU, Lissichkov T, Aldaoud A et al. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia: results of an international Phase III study. Blood 110, (2007) (Abstract 2043).
34. Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 8, 2319-2325 (2001).
35. Johnson S, Smith AG, Löffler H et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. Lancet 347, 1432-1438 (1996).
36. Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96, 2723-2729 (2000).
37. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107, 885-891 (2006).
38. Flinn IW, Neuberg DS, Grever MR et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 25, 793-798 (2007).
39. Eichhorst BF, Busch R, Wendtner CM et al. Comparison of the efficacy and toxicity of fludarabine (F) in first line therapy of younger versus elderly patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a meta-analysis of two Phase III trials of the German CLL study group (GCLLSG). Blood 106(11 Suppl.), (2005) (Abstract 717).
40. Hallek M, Fingerle-Rowson G, Fink A-M et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL). Blood 112, (2008) (Abstract 325).
41. Ferrajoli A, O'Brien S, Wierda W et al. Treatment of patients with CLL 70 years old and older: a single center experience of 142 patients. Leuk. Lymphoma 46(Suppl. 1), S86 (2005) (Abstract 95).
42. Eichhorst BF, Busch R, Stauch M et al. No significant clinical benefit of first line therapy with fludarabine (F) in comparison to chlorambucil (Clb) in elderly patients with advanced chronic lymphocytic leukemia (CLL): results of a Phase III study of the German CLL Study Group (GCLLSG). Blood 110, (2007) (Abstract 629).
43. Morrison VA, Rai KR, Peterson BL et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil in infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B9011. J. Clin. Oncol. 19, 3611-3621 (2001).